Sharon Barr to succeed Pangalos at AZ

AstraZeneca plc (LSE:AZN; NASDAQ:AZN) named Sharon Barr as EVP, biopharmaceuticals R&D and successor to Mene Pangalos, who is retiring early next year after almost 14 years at the company. Barr, who will lead discovery through to late-stage development across cardiovascular, renal and metabolism, and respiratory & immunology, has been SVP, head of research and product development at Alexion Pharmaceuticals Inc., AZ’s rare disease group, since 2013. She will join the pharma’s senior executive team Aug. 1.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) hired Angus Grant as EVP, business development. Grant joins Teva from BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235), where he was chief business executive. ...